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Abstract 
Recent years have seen a dramatic increase in interest in the use of ring-opening polymerization 
of N-carboxyanhydride (NCA) monomers as a method to prepare well-defined polypeptides and 
peptide-hybrid materials. The resulting molecules are often capable of assembling into a variety 
of different structures, including micelles, vesicles, nanoparticles and hydrogels, and therefore 
have been explored as novel drug delivery systems.  Peptides are attractive in this regard due to 
their rich chemical functionality and ability to assemble through the formation of secondary 
structures (for example -helices and -sheets).  In addition, they are inherently biodegradable 
and biocompatible.  This review describes recent advances in the field, covering aspects such as 
improved methods with which to prepare better-defined polypeptides, crosslinking of assemblies 
to enhance biostability, the preparation of materials that respond to a variety of stimuli (including 
light and intra- or extracellular redox conditions), functionalization with targeting ligands to 
enhance cellular uptake, assemblies for siRNA delivery and approaches to theranostic systems.  
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Introduction 
Even after decades of research, efficient drug delivery to diseased tissues still represents a 
significant challenge. The small molecule nature of most potent drugs is largely responsible as 
they frequently possess poor solubility, undergo rapid metabolism and can freely diffuse in both 
healthy and diseased cells resulting in non-specific distribution in the body. The use of 
macromolecular drug delivery systems has proven very successful in increasing the efficacy of 
delivery of such therapeutics due to their increased circulation time and enhanced ability to enter 
and be retained within tumors. 
Polypeptide-based materials are ideal for drug delivery systems due to their biocompatibility, 
biodegradability, tunable structural architecture and ability to form secondary structures.  
Amphiphilic polypeptide materials can self-assemble into a plethora of different architectures 
through non-covalent interactions, possessing the ability to encapsulate and deliver drugs. By 
adopting ordered conformations such as α-helices and β-sheets, the use of polypeptide-based 
materials allows better control over nanoscale structure formation. The self-assembly of 
amphiphilic polymers can be directed by controlling chemical and physical parameters, such as 
hydrophobic-hydrophilic ratio, molecular weight and chemical nature.1,2 A straightforward route 
to synthetic polypeptide materials is through ring opening polymerization (ROP) of N-
carboxyanhydrides (NCAs).3-5 NCAs are versatile precursors to homo-polypeptides and block 
copolypeptides. The polymerization technique is particularly useful in the design of peptide-
hybrid materials, which combine peptide segments with non-peptidic macromolecular 
architectures. These hybrids hold great potential due to the combination of the desirable features 
of non-peptidic synthetic polymers, such as solubility and processability, with those of 
polypeptides i.e. secondary structure and biocompatibility.6,7 
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Recently, an abundance of research has been carried out into the use of polypeptide-based 
vehicles as drug delivery systems. Assemblies such as micelles, vesicles, hydrogels, nanogels, 
capsules, fibres, dendritic and macromolecular drug conjugates, nucleic acid complexes and 
polyplexes have all been reported.8-15 Some of the systems are well established and investigated, 
and are currently in clinical trials.9,16 Most of the formulations in clinical use or trials at the 
moment are simple monofunctional micellar systems. The next phase of drug delivery research, 
already well underway, is the introduction of multifunctionality to the systems to achieve highly 
efficient delivery, with minimal side effects for the patient. The ultimate drug delivery system 
should have a number of important additional characteristics as well as biocompatibility; it 
should be stable to dilution in biological media, have stealth properties to avoid uptake by the 
reticuloendothelial system and only release drug at the required site in a controlled manner. 
Methodology to achieve these goals is under intense investigation. The biostability of delivery 
systems can be enhanced by modification of the chemical building blocks for crosslinking. 
Stealth properties can be introduced into carriers through incorporation of synthetic polymers 
with inherent stealth properties such as poly(ethyleneglycol) (PEG). A number of approaches can 
aid release of drugs specifically in the required tissues, including introduction of stimuli-
responsiveness to systems and creation of systems that actively target certain cells or certain cell 
characteristics. Recently, a number of thorough reviews have been published on the subject of 
polypeptides, poly(amino acids) and stimuli responsive drug delivery systems.5,7,10,12,16-18 
This review will focus on the latest advances in multifunctional polypeptide-based drug delivery 
systems created solely from ROP of NCAs. Initially an overview of the synthetic strategy, i.e. 
ROP of NCAs, will be given. In the remaining sections block copolypeptides and peptide-hybrid 
block copolymer systems which form nanoparticles (micelles and vesicles primarily), will be 
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discussed in terms of (I) increasing the biostability of the systems, (II) stimuli responsiveness, 
(with particular focus on redox- and photo-responsive systems) and (III) recent advances in 
active targeting and additional functionalities. There will be some overlap in the sections 
especially with regards to stimuli-responsiveness, as the majority of the systems discussed are 
multifunctional. 
Synthetic Strategy: ROP of NCAs 
Reports of ROP of NCAs have been widespread in the literature for over 100 years since their 
first introduction by Leuchs et al.4,19,20 The polymerization is most commonly initiated by 
primary amines, however, the existence of two possible mechanisms, namely the normal amine 
mechanism (NAM) and activated monomer mechanism (AMM) has always rendered it 
problematic to gain precise control of the reaction (Figure 1). Nonetheless, in the past number of 
years there have been major advances in this area making ROP of NCAs a convenient and 
efficient method to generate synthetic polypeptides and peptide-based block copolymers on a 
multi-gram scale. The key to gaining control is to prevent or at least limit the AMM route.  This 
can be achieved in a number of ways.  Deming et al. employed transition metal catalysts which 
undergo oxidative addition with NCA monomers thus preventing deprotonation of the NCA N-H 
21,22.  Lu et al. used trimethylsilylated primary amines which produce NCA ROP via a group 
transfer mechanism.23,24  Both types of initiator significantly reduce the polymerization time, as 
well as allowing precise control and resulting in well-defined polymers. Schlaad and co-workers 
utilized simple amine hydrochloride salts as initiators resulting in good control but with longer 
reaction times (e.g. three days).25 The use of highly purified NCA monomers (e.g. via flash 
column chromatography), the optimization of experimental technique (e.g. high vacuum) and 
investigation of reaction conditions (e.g. temperature, pressure) can also result in good control.26-
6 
 
29  In work comparable to that of Schlaad, Conejos-Sánchez et al. have reported using 
ammonium salts with non-nucleophilic tetrafluoroborate anions as initiators for the ROP.30 Most 
recently, Zou et al. have detailed a facile method for well-controlled ROP of NCAs involving 
simply flowing nitrogen through the polymerization mixture.31 
Non-peptidic synthetic polymers with terminal amines can also be used as initiators for the ROP 
resulting in peptide-hybrid copolymers, where one block is a homo-poly(amino acid) and the 
other is a synthetic polymer with advantageous properties. These peptide hybrid block 
copolymers have potential inherent biocompatibility and stealth properties owing to the 
properties of the non-peptidic polymers used such as PEG. PEG is widely used as the hydrophilic 
portion of amphiphilic block copolymers as it facilitates solubility in aqueous solution through 
steric stabilization, prevents protein adsorption and can protect the peptide block from enzymatic 
degradation. This results in decreased uptake by the liver, increased circulation time in the 
bloodstream and thus enhanced bioavailability. A number of excellent reviews have previously 
been published on this topic.5,6 
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Figure 1 Mechanisms for ROP of NCAs when using primary amine initiation  
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1. Crosslinking for Increased Biostability 
After biocompatibility, one of the most basic requirements of a drug delivery system is stability 
in the body. If a system is not stable in biological fluids this could result in burst release of the 
payload in non-targeted areas. Increased stability results in increased blood circulation time and 
increased bioavailability. The most commonly used method for increasing the stability of 
systems is crosslinking. Table 1 depicts a summary of the crosslinked nanoparticles that are 
discussed in this section. Nanoparticles can be shell-crosslinked or core-crosslinked or both. 
Shell-crosslinked particles can obstruct burst release of the encapsulated drug, while crosslinking 
the particle core can enhance the stability of the systems by preventing disintegration on dilution. 
Crosslinking can be carried out using small molecule crosslinking agents or by stimulating the 
self-crosslinking ability of certain systems for example with UV light. There are occasionally 
some disadvantages associated with crosslinking including complicated crosslinking routes and 
low reaction efficiency, extensive purification and expensive crosslinkers. Systems with the 
ability to self-crosslink bypass such problems and usually involve mild conditions thereby 
eliminating inter-particle crosslinking and avoiding aggregation. Additionally, in some 
circumstances it is not desirable to decrease the biodegradability of the particle and slow the 
release of the payload. Some recent advances have been made to avoid potential problems in this 
area, such as the introduction of unimolecular micelles and tri-domain particle systems wherein 
neither the shell nor the core is the crosslinked region, thereby not interfering with drug action or 
release. 
Table 1 Summary of crosslinked particles discussed and their responsiveness 
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Polymer Architecture Crosslinker Responsiveness Reference 
PEG-PAsp-P(Leu-co-
Tyr) 
Micelle  Iron (II) Chloride pH 31 
PEG-PAsp-PPhe Micelle Ketal pH 32 
PEG-PAsp Micelle 1,6-hexanediamine pH 33 
PGA-PLys-r-DOPA Vesicle Oxygen pH 39 
PEG-PCys-PPhe Micelle Hydrogen peroxide Redox 41 
PEG-PCys-PGA Nanogel Cys NCA Redox 43 
PEG-Cys-Phe (Star) Nanogel (Unimolecular 
micelle) 
Cys Redox 44 
PLys-ss-PEG Micelle Cystamine Redox 46 
PEG-P(propargyl-Glu) Micelle Bis(Z-azidoethyl) 
disulfide (BADS) 
Redox 47 
P(diethyleneglycol-L-
Glu)-tetramine (Star) 
Micelle (unimolecular) Disulfide tetramine Redox 48 
PEG-P(Glu-co-
cinnamyl-Glu) 
Micelle UV light Photo 37 
PEG-P(cinnamyl-Glu) Micelle UV light Photo 38 
 
 1.1 Crosslinking with External Factors (small molecule agents, self- and photo-crosslinking) 
1.1.1 Micelles 
Tri-domain micellar systems with core-shell-corona morphology have recently been reported by 
Rios-Doria et al.32 The system is pH-responsive and based on PEG-b-poly(aspartic acid)-b-
poly(D-leucine-co-tyrosine). The poly(D-leucine-co-tyrosine) comprises the core (drug reservoir) 
and PEG forms the corona with a middle layer or shell of poly(aspartic acid). Using iron (II) 
chloride, crosslinks are formed between the metal and the carboxylic acid groups of the 
poly(aspartic acid) layer, which allows release of drug at low pH such as that found in a tumour 
microenvironment. The system is versatile and capable of encapsulating a range of hydrophobic 
anticancer drugs with high loading efficiency, due to the use of both D- and L- stereoisomers of 
amino acids in the core of the micelles. This disrupts the secondary helical structure of the 
polypeptide introducing a random coil structure thereby allowing for greater drug loading. The 
crosslinked systems displayed enhanced stability in vivo. A similar approach has been taken by 
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Lee et al. who have reported core-shell-corona micelles consisting of PEG-poly(L-aspartic acid)-
poly(L-phenylalanine) on this occasion with pH hydrolysable ketal crosslinks (Figure 2).33 Later, 
Bae and coworkers crosslinked the poly(aspartate) portion of diblock PEG-poly(aspartate) 
nanoassemblies with 1,6-hexanediamine using carbodiimide coupling.34 Grafting to synthesize 
hyperbranched polymers is also a method of potentially increasing the stability of assemblies. By 
preparing grafted nanoassemblies, where PEG-poly(benzylaspartate) grafts were conjugated to 
PEG-poly(aspartic acid), a comparison of the stability of both grafted and crosslinked systems 
was possible. The crosslinked systems proved to be much more stable and were shown to 
encapsulate doxorubicin and release it in a controlled manner in response to pH. 
 
Figure 2 Illustration of shell cross-linking of doxorubicin-loaded polymer micelles with a pH-labile ketal 
cross-linker and intracellular release triggered by endosomal pH33.  Reprinted with permission from Lee 
et al., Biomacromolecules, 2011, 12, 1224-1233. Copyright 2011 American Chemical Society. 
 
Photo-crosslinkable systems are desirable as the process is usually fast, effective, can be well-
controlled and achieved in mild conditions. Systems that exploit similar photo-responsiveness for 
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triggered drug delivery functions will be discussed in detail later. One of the most frequently 
used photo-crosslinkable groups is the cinnamic group due to its excellent UV responsiveness.35-
37 Ding et al. reported photo-crosslinkable micelles based on diblock and triblock copolymers of 
PEG-poly(L-glutamic acid-co-γ-cinnamyl-L-glutamate) prepared by post-ROP modification of 
the glutamic acid block with cinnamyl alcohol.38 Upon UV exposure the micelles were 
crosslinked in water and were shown to be able to release the drug Rifampin. In comparable 
work, Yan et al. have reported photo-crosslinked micelles based on PEG-poly(γ-cinnamyl-L-
glutamate) this time from polymerization of a cinnamyl-modified NCA monomer.39 The latter 
method resulted in better control over functionalities and architectures.  It was possible to load 
and release Paclitaxel from the micelles, with the crosslinked systems displaying a slower release 
rate than the non-crosslinked. 
1.1.2 Vesicles 
Micelles are the forerunners of drug delivery systems and have been extensively studied.7 
However, polymer vesicles or polymersomes are emerging as more versatile systems since they 
can be used to deliver both hydrophobic and hydrophilic drugs simultaneously. While numerous 
reports of micelle crosslinking exist, there are relatively few dealing with the crosslinking of 
vesicles.  Deming and coworkers prepared DOPA-containing diblock copolypeptides that self-
assembled into vesicles.  The DOPA residues were crosslinked under oxidative conditions which 
produced a marked increase in membrane stability.40  Another example was reported by Sulistio 
and co-workers, where the inner layer of the shell of a polypeptide vesicle was crosslinked via an 
oxygen-mediated process.41 The vesicles were based on poly(glutamic acid)-block-poly(lysine)-
ran-(3,4-dihydroxyphenylalanine) (DOPA) formed by hexamethyldisilazane-initiated ROP of the 
corresponding NCAs. Crosslinking the vesicles was carried out at pH 12 where the poly(lysine)-
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ran-poly(DOPA) block forms the core of the particle. In situ crosslinking with oxygen resulted 
in the oxidation of the phenolic groups of the DOPA residues to DOPA-quinone species, which 
then underwent dimerization or attack by the pendent amines of the lysine residues. The 
crosslinked vesicles were shown to be more stable than the non-crosslinked counterparts, 
maintaining their structure when the pH was lowered to 3, whereas the non-crosslinked ones 
changed their configuration (Figure 3).  
 
              
Figure 3 (a) Crosslinking of DOPA at pH 12 via generation of DOPA-quinonic intermediates (b) TEM 
image and (c) AFM image with z-profile analysis of the cross-linked vesicle from PLGA-b-P(LL-r-
DOPA) block copolymers self-assembly at pH = 12. (d) The proposed structure of the cross-linked vesicle 
at pH = 12.  Reproduced with permission (John Wiley & Sons) from 41. 
 
1.2 Crosslinking with disulfide bonds: Redox-responsive polymers  
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A popular method of introducing crosslinking into systems is through the use of disulfide bonds, 
which can result in redox-responsive polymers.42 The development of polymers, which respond 
differently to intra- and extracellular redox conditions is a promising area in tailored drug 
delivery. Redox-sensitive nanoparticles are selectively cleaved in the cytoplasm by glutathione 
(GSH), a tripeptide found in cells at millimolar concentrations which degrades disulfide bonds to 
the corresponding thiols. Disulfide bonds can be introduced into block copolymers by using 
disulfide-containing monomers or disulfide-containing crosslinkers/initiators. 
1.2.1 Nanoparticles from Disulfide-containing Monomers 
In order to create redox-responsive polypeptides, monomers containing cysteine are the most 
commonly used. Wang et al. prepared redox-sensitive shell cross-linked PEG-polypeptide hybrid 
micelles with core-shell-corona morphology based on PEG, cysteine and phenylalanine.43 The 
micelles were self-crosslinkable through the oxidation of the thiol groups on the poly(cysteine) 
portion, using dilute hydrogen peroxide. In vitro drug release studies show that the micelles 
could rapidly release the drug payload in response to the intracellular GSH level, and reduce 
drug loss in the extracellular environment.  
Disulfide-containing nanoparticles can also be core-crosslinked and when this is the case they 
are sometimes termed nanogels.41,44 A core-crosslinked nanogel with potential drug delivery 
applications has been reported by Xing et al.45  The nanogel is prepared by the ROP of two 
NCAs, L-cysteine and γ-benzylglutamate initiated by an amine-terminated PEG to form a 
peptide-hybrid copolymer with stealth properties. The cysteine NCA is a bifunctional monomer 
in that it can act as both a monomer and crosslinker via the disulfide linkages.  The resultant 
nanogel had a core-shell structure as evidenced by DLS, TEM and AFM with a size of 250 nm. It 
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disassembled in the presence of dithiothreitol (DTT) indicating crosslinking of the core by 
disulfide bonds. An investigation into the loading and release of the anti-cancer drug 
indomethacin was carried out showing efficient loading and release behaviour.  
As aforementioned, crosslinking can have some limitations and unimolecular micelles, such as 
those formed from multi-arm star amphiphilic polymers, can be used as alternatives since they 
commonly display enhanced stability without hindering drug release. Ding and co-workers 
reported star copolymers created from ROP of L-cysteine and L-phenylalanine initiated by 
amine-terminated PEG.46 The polymers were shown to form redox-responsive nanogels in 
solution and accelerated release of doxorubicin was observed in GSH pretreated HeLa cells as 
opposed to non-pretreated cells. 
1.2.2 Nanoparticles from Disulfide-containing Linkers/Initiators 
Use of disulfide-functionalized initiators to carry out the polymerization is an efficient method of 
introducing redox-responsiveness. Ding et al. have recently shown the increased efficacy of 
redox-responsive micelles based on poly(lysine) created by ROP of the lysine NCA, initiated by 
disulfide-functionalized PEG.47 Doxorubicin was loaded into the micelles and the 
biocompatibility (hemolytic, cell and tissue compatibilities) were proven. Ren and co-workers 
have reported sheddable micelles which can detach their shells upon reduction stimulus, 
prepared in a similar manner using a cystamine-conjugated PEG to initiate the ROP of leucine 
NCA.48 The micelles showed accelerated doxorubicin release in the presence of DTT; 40% of 
the drug was released within 12 hours in the presence of DTT whereas it took 100 hours to 
release only 25% in the absence. 
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Redox-responsive crosslinked micelles can also be achieved using click chemistry. Cheng et al. 
prepared micelles from the self-assembly of PEG-b-poly(γ-propargyl-L-glutamate) generated 
from NCA polymerization.49 The micelles were subsequently crosslinked by click chemistry 
between bis(2-azidoethyl)disulfide (BADS) and the pendent alkynyl groups. Crosslinking was 
found to increase the stability of the micelles as well as increasing the drug-loading capacity due 
to the compacted crosslinked core. The micelles showed an accelerated release profile of 
doxorubicin in reductive conditions and higher cell proliferation inhibition towards HeLa cells 
pre-treated with glutathione. 
A more inherently stable unimolecular star system was recently introduced by Liu and co-
workers.50 These dual-responsive redox-sensitive and thermo-responsive micelles were prepared 
by ROP of diethyleneglycol-L-glutamate initiated by a tetra(amine) with a disulfide-bond core. 
An attractive feature of these systems is that they also form hydrogels at certain concentrations 
(<4 wt%). They were shown to be redox- and thermo-responsive and to have the mechanical 
properties that can be controlled by the disulfide bond core and star shape (Figure 4). 
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Figure 4 Illustration of dual stimuli-sensitive micellization and hydrogelation process of star polypeptide.  
Reproduced from Ref. 50 with permission from The Royal Society of Chemistry. 
 
 2. Advances in Stimuli-Responsive/Triggered Release  
As demonstrated by the preceding discussion on redox-responsive examples, one of the most 
exciting areas of growth in drug delivery is the development and advancement of stimuli-
responsive polypeptide delivery systems. Very intricate and elegant systems have been reported 
over the past two decades.51,52 Multifunctional stimuli-responsive or ‘smart’ polypeptide drug 
delivery materials allow increasing control over the release of payloads, combining the 
possibility of efficient delivery to the required sites with decreased distribution of payloads in 
unwanted areas of the body. There are many other external stimuli that can be harnessed in a 
similar manner to redox, including pH, temperature, light, ultrasound, electronic and magnetic 
fields, biomolecules, enzymes and chemicals. A number of excellent reviews on stimuli 
responsive polymer systems have been published previously.17,53,54  This part of the review will 
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focus on recent developments in light responsive polypeptide particle systems in particular and 
their use in drug delivery. 
2.1 Photoresponsive Systems 
Recently, photoresponsive drug delivery vehicles have come to the forefront of polymer research 
owing to the precise spatial and temporal control that such systems allow.55 Light-responsive 
carriers possess non-invasive stimuli responsiveness, biocompatibility and remote activation and 
also offer the possibility of quick release of payload as compared to other stimuli-sensitive 
carriers e.g. pH-responsive. A number of photoresponsive moieties are regularly used in this area 
including nitrobenzyl, azobenzene and spiropyran groups. Light-responsive systems can be 
prepared by homo-/copolymerization of photoresponsive monomers, by post-polymerization 
functionalization or by initiation of the polymerization with the photoresponsive moiety.  
Most recently Liu et al. have reported the first synthesis of a photoresponsive polypeptide-hybrid 
polymer from ROP of a photoresponsive S-(o-nitrobenzyl)-L-cysteine N-carboxyanhydride, 
initiated by amino-terminated PEG.56 The polymers were shown to self-assemble into spherical 
nanoparticles in aqueous solution and displayed a reduction in size after irradiation, indicating 
their responsiveness to light. Controlled release of doxorubicin was achieved by changing the 
light irradiation times which induced the gradual photocleaving of the poly(nitrobenzylcysteine) 
core of the particles and reduction in micelle diameter (Figure 5). 
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Figure 5 Schematic representation of self-assembly and photo-triggered drug release from poly(S-(o-
nitrobenzyl)-L-cysteine)-b-PEG56.  Reprinted with permission from Liu & Dong, Biomacromolecules 
2012, 13, 1573-1583. Copyright 2012 American Chemical Society 
 
There are a number of reports of photoresponsive amphiphilic block copolymers with spiropyran 
(SP) and azobenzene groups attached, which are also activated by UV-visible light. Mezzenga et 
al. reported the preparation of photoresponsive polypeptide-hybrid diblock copolymers based on 
a SP-modified poly(glutamic acid) by post-polymerization modification, from amine-terminated 
PEG-initiated ROP (Figure 6).57 The glutamic acid was functionalized with SP groups via 
esterification of the free carboxylic acid groups after deprotection of the benzyl moieties. The 
amphiphilic block copolymers self-assembled into flower-like micelles and micellar aggregates. 
Dissolution and assembly of micelles was shown to be controllable by light, although no drug 
loading or release data was reported. 
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Figure 6 Schematic representation of photoresponsive micellization-dissolution process for spiropyran-
poly(glutamic acid)-b-PEG57.  Reprinted with permission from Kotharangannagari et al., Macromolecules 
2011, 44, 4569-4573. Copyright 2011 American Chemical Society. 
 
One of the drawbacks, however, of using UV light is the lack of penetration into tissues and the 
possibility of tissue damage. As an alternative, near-infrared light (NIR), can penetrate deep into 
tissues with less damage than UV or visible light and as such would be a highly desirable method 
for control of drug release. Kumar et al. have reported the development of a NIR light-sensitive 
polypeptide block copolymer by functionalizing poly(glutamic acid)-PEG hybrids with a number 
of NIR two-photon-absorbing chromophores.58 Upon exposure to NIR light the chromophore is 
photocleaved, destabilizing the micelle due to a shift in the hydrophobic-hydrophilic balance. 
NIR-responsive release of the antibacterial drug Rifampicin (RIF) and the anti-cancer agent 
Paclitaxel (PCT) were investigated separately.  
19 
 
There are a number of systems which combine different types of stimuli sensitivity displaying 
multi-stimuli responsiveness.53 Light-sensitive and temperature-sensitive triblock copolymers 
based on two PEG-poly(alanine) diblocks coupled by an azobenzene were reported by Jeong et 
al.59 Exposure to UV light switches the azobenzene to its trans form and larger micelles are 
formed in aqueous solution as opposed to the cis form. The system is also temperature-
responsive due to the PEG-poly(alanine) blocks and as such shows good potential as a drug 
delivery vehicle although no drug studies have been reported. 
2.2 Other Systems 
Chemical substances are also being explored as stimuli for drug delivery.60 An advantage of this 
method of stimulation is that the activity and concentration of chemical substances can be easily 
controlled by external modification, which is not the case with other stimuli. Recently, Wang et 
al. introduced the possibility of using β-cyclodextrin as a trigger molecule by incorporating 
adamantane into micelles and thereby making use of host-guest chemistry. The N-
hydroxysuccinimide ester of adamantanamine was coupled to Z-L-lysine and subsequently 
converted to the NCA (lys(Ad) NCA) using α,α-dichloromethylmethyl ether. ROP of this NCA 
was carried out using a tetra-amino-modified PEG (TAPEG) resulting in a four-armed block 
copolymer capable of forming micelles in solution (PLys(Ad)2-b-PEG-b-PLys(Ad)2). The 
diameter of the micelles in response to β-cyclodextrin was measured, and the assemblies were 
shown to be dissociated after 24 hour exposure. In the absence of β-cyclodextrin the micelles are 
very stable with no change in diameter over two weeks. The release of doxorubicin from the 
micelles was found to be accelerated in the presence of β-cyclodextrin (Figure 7). 
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Figure 7 Schematic illustration of the formation of micelles and triggered drug release mechanism60.  
Reprinted with permission from Wang et al., Macromolecules 2013, 2, 201-205. Copyright 2013 
American Chemical Society. 
 
3.0 Functionalization for Active Targeting and Promotion of Cell Uptake  
The majority of the drug delivery systems discussed thus far act via passive targeting, namely the 
enhanced permeation and retention (EPR) effect which results in accumulation of the particles in 
tumours. The ability to actively target specific cells is desirable for increased efficiency of 
delivery and reduced side effects. A number of micelles with active targeting capabilities are in 
clinical trials.9 There are several of methods of functionalizing polypeptides with targeting 
ligands including post-polymerization modification, for example conjugation using click 
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chemistry,29,61 or polymerization of NCA monomers with attached functional moieties.62,63  
Many targeting ligands have been incorporated into various polypeptide systems. The nature of 
the ligand usually exploits the fact that its receptor is over-expressed on the surface of the 
diseased cells. This section will present recent developments in targeting in terms of the ligands 
used for targeting functionalization, namely sugars, folic acid and transferrin. In addition, 
polypeptides with functionality required for siRNA delivery and for use as theranostic systems 
will briefly be discussed. 
3.1 Functionalization with Sugars 
The use of sugars for targeting is widespread in the literature as glycopeptides have many 
therapeutic and biotechnological applications.64,65 Stöhr et al. detailed the preparation of glyco-
NCAs through the attachment of peracetylated sugars (glucose, mannose, galactose) via a 
thiourea linker to the ε-amino group of α-Boc-lysine and α-Z-lysine. The corresponding NCAs 
were copolymerized with PEGylated lysine NCA and ε-TFA-Lysine-NCA and both the sugar 
residues and lysine units were subsequently deprotected. The peptide-hybrids were shown to be 
specifically taken up by human T lymphocytes at 37 °C demonstrating good potential as drug 
delivery systems.66  
Previously, Huang et al. reported saccharide-decorated amphiphilic block copolymers via post-
polymerization functionalization.67 The poly(L-lysine)-block-poly(L-tyrosine) copolymers were 
capable of forming both micelles and vesicles, which could be crosslinked by UV irradiation via 
dimerization of the tyrosine residues thus increasing the biostability. The disaccharide 
lactobionolactone, was coupled to the free amino groups on the lysine segment post-
polymerization, in order to introduce galactose residues that act as a targeting group to 
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hepatocytic cells and also to help combat the innate cytotoxicity of poly(lysine). These 
glycopeptide nanoparticles, Lac-g-P(Lys)-b-P(Tyr), were investigated for release of fluorouracil 
and doxorubicin and were shown to do so rapidly upon enzymatic degradation of the assemblies 
(Figure 8). This system is multifunctional, and combines a number of the desired aspects of an 
efficient delivery system such as targeting via the saccharide ligand and enhanced stability 
through crosslinking. 
 
 
Figure 8 (I) Synthesis of Lac-g-P(Lys)-b-P(Tyr) block copolypeptides; (II) TEM images of (a) self-
assembled aggregates from Lac-g-P(Lys)66P(Tyr)22 and (b) the Dox-loaded Lac-g-P(Lys)66P(Tyr)22 
particles.  Reprinted with permission (Elsevier) from 67. 
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More recently, this group have detailed the preparation of similar multifunctional vesicles based 
on saccharide- and hexanoyl- modified poly(L-lysine). The amphiphilic nature of the polymer 
and thus the size of the vesicles, is dictated by the saccharide and hexanoyl substitution. The 
vesicles can actively target HepG2 cells through the saccharide ligand, they are pH responsive 
and display increased stability via crosslinking with genipin. A high level of drug loading was 
achieved through sonication and the application of a pH gradient between the outside and inside 
of the vesicles. The vesicles showed accelerated drug release at acidic pH and the rate could be 
tuned by the degree of crosslinking, resulting in a very promising drug delivery system. 
3.2 Functionalization with Folic acid  
Folate-decorated systems have been investigated for many types of polymers including 
polypeptide-based, as folate receptors are over-expressed on the surface of certain types of 
cancer cells. Previously, a targeted polypeptide-based multifunctional micellar system was 
reported by Bae et al. 68 The micelles were composed of PEG-poly(aspartate), decorated with 
folate and conjugated to a drug, adriamycin, via a hydrazone linkage. This system incorporates 
targeting, stealth properties and an already conjugated drug. The efficacy of folate-PEG-
(polyaspartate-hydrazone-adriamycin) micelles was compared with that of non-targeted  micelles 
and the effective dose of the targeted system improved. 
More recently, core cross-linked star polymers composed of a poly(l-cysteine) core and poly(l-
lysine) arms were functionalized with a PEG-folic acid conjugate via thiol-ene click chemistry 
resulting in poly(PEG-b-L-Lysine)arm-poly(L-cysteine)core stars.
44 Uptake of the folate-conjugated 
and non-folate-conjugated version of the stars was investigated with the breast cancer cell line 
MDA-MB-231. The folate-conjugated star polymer was shown to display cell association and 
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internalization for 55% of cells after 3 hours of incubation. In the case of the star polymers 
lacking the folate ligand, only 13% of cells displayed a low level of non-specific attachment, 
indicating the polymers are promising as cancer targeting drug delivery vehicles. 
 
Figure 9 Schematic illustration of folic acid decorated poly(PEG-b- L-Lysine)arm-poly(L-cysteine)core stars 
and an image of their internalization in breast cancer cell line MDA-MB-231.44  Reprinted with 
permission from Sulistio et al., Biomacromolecules 2011, 12, 3469-3477. Copyright 2011 American 
Chemical Society. 
 
3.3 Functionalization with Transferrin  
Deming and coworkers previously reported block co-polypeptide vesicles based on poly(arginine) 
and poly(leucine).69,70 In order to overcome the cytotoxicity associated with the positive charge 
due to the arginine, the less cytotoxic poly(L-glutamate) was used as the hydrophobic block. This 
alteration however, means that the vesicles are unable to enter cells unaided and in order to 
enhance the internalization an iron-binding glycoprotein, transferrin was conjugated. An 
increased uptake of the vesicles in cells was observed, however, it was found that the vesicles 
traffic to early endosomes but not lysosomes, indicating the possibility they are recycled back to 
the cell surface. This observation may create an opportunity for the design of more advanced 
25 
 
vesicles equipped with an endosome-disrupting function to allow increased localization of the 
assemblies in the cytosol, where it would be required to release the payload.  
 
 
Figure 10 (a) Schematic representation of poly(glutamic acid)-poly(leucine) vesicles (b) Schematic 
illustration of transferring-receptor binding and the resultant difference in internalization in cells70.  
Reprinted with permission from Choe et al., Biomacromolecules 2013, 14, 1458-1464. Copyright 2013 
American Chemical Society. 
 
Interestingly, the functional moiety does not necessarily need to be conjugated to the particle to 
have an effect on its targeting ability as evidenced by Song et al., who have shown that simply 
co-administering the tumor-penetrating peptide internalizing(Arg-Gly-Asp-D-Phe-Cys (iRGD) 
was sufficient to enhance the targetability of their cisplatin-loaded PEG-poly(glutamic acid) 
micelles.17  
(a) 
(b) 
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3.4 DNA and siRNA Delivery 
One of the most promising areas of therapy for the future is delivery of small interfering RNAs 
(siRNA). A number of problems are associated with siRNA delivery, such as a short serum half-
life and poor cellular internalization ability, which can possibly be overcome through the use of 
polypeptide-based delivery vehicles. A recent paper by Zheng et al. combines the approaches of 
drug and gene delivery by preparation of a nanoparticle capable of co-delivering a 
chemotherapeutic drug and an siRNA.71  The system is comprised of a tribock copolymer of 
PEG-b-poly(L-lysine)-b-poly(L-leucine) and was loaded with docetaxel and siRNA-Bcl-2. 
 
Figure 11 (A) Schematic illustration of self-assembly of PEG-poly(lysine)-poly(leucine) vesicles and 
siRNA loading; (B) TEM of vesicles; (C) zeta potential of vesicles.  Reprinted with permission (Elsevier) 
from 71.  
 
Gabrielson et al. have designed a library of cationic, helical polypeptides based on the 
architectural characteristics of cell penetrating peptides. A number of the polymers have been 
shown to effectively mediate gene delivery while at the same time maintaining the membrane 
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destabilization properties associated with helicity which facilitate cell penetration.72  
Polypropyleneimine-poly(L-lysine) (PPI-PLL) dendritic core star polymers were also 
investigated for plasmid DNA and siRNA complexation and compared to linear PLL73.  A 300-
fold increase in DNA transfection ability was observed in the case of the star polymers, which 
was attributed to their ability to form well-defined spherical polyplexes of around 100nm 
diameter. 
3.5 Theranostic Systems 
Another growing area is incorporating imaging ability into the delivery systems i.e. 
multifunctional theranostics. An interesting example of this was reported by Sanson and co-
workers who developed multifunctional vesicles for combined therapy and imaging.74 Block 
copolymer vesicles based on poly(trimethylene carbonate) (PTMC) and poly(glutamic acid) were 
loaded with both hydrophobically-modified magnetic nanoparticles, maghemite (γ-Fe2O3) and 
the anti-cancer drug doxorubicin. Synthesis of the block copolymer was carried out by ROP of 
an amine-terminated PTMC. The magnetic particle-loaded vesicles demonstrated the ability to be 
guided by a permanent magnetic field gradient and proved useful for magnetic resonance 
imaging (MRI), showing enhanced contrast. Release of doxorubicin from the dually-loaded 
vesicles was enhanced by the application of an RF oscillating magnetic field. 
Recently, Xiao et al. reported multifunctional, unimolecular micelles with enhanced stability, 
combining active targeting and stimulus-responsive drug delivery with positron emission 
tomography imaging ability.75 The polymers were composed of Boltorn H40-poly(ι-glutamate-
hydrazone-doxorubicin)-b-poly(ethylene glycol) conjugated with cyclo(Arg-Gly-Asp-D-Phe-
Cys)(cRGD) for targeting and macrocyclic chelators (1,4,7-triazacyclononane-N, N’, N’’-
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triacetic acid) [NOTA] for 64Cu-labeling and PET imaging (H40-DOX-cRGD). Boltorn H40 is a 
hyperbranched polyester and synthesis of H40-DOX-cRGD involves ROP of benzyl glutamate 
NCA with PEG macroinitiators. Doxorubicin was conjugated to the poly(glutamic acid) portion 
of the micelle via a pH-sensitive hydrazone linkage after conversion of the benzyl groups to 
hydrazide groups through an ester-amide exchange reaction. The intricate synthesis of the 
multifunctional system is shown in figure 12. 
 
Figure 12 Synthetic scheme for multifunctional micelles Boltorn H40-poly(L-glutamate-hydrazone-
doxorubicin)-b-PEG decorated with cRGD and NOTA.75 
This micellar system showed accelerated release of the conjugated doxorubicin at lower pHs. 
cRGD conjugation resulted in increased accumulation of the assemblies in human glioblastoma 
cells via αvβ3-integrin endocytosis, compared to the control micelles lacking the cell penetrating 
peptide sequence. PET imaging using the 64Cu-labelled micelles also showed greater 
accumulation of the targeted assemblies in the tumor cells which was further corroborated by 
biodistribution and ex-vivo fluorescence imaging. This example shows the potential power of 
multifunctional drug delivery systems. 
Summary and Future Perspective 
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Throughout this review recent advances in the design and preparation of polypeptide-based 
assemblies with the potential for drug delivery use have been discussed. The developments in the 
efficiency and control of the ROP of NCAs have made the explosion in polypeptide-based drug 
delivery systems possible. A large volume of foundation work on self-assembling peptide-based 
materials has been carried out over the past few decades and now the task of improving and 
increasing the efficacy of the existing systems through multifunctionality, is underway. 
Biocompatibility and biostability are essential considerations when it comes to the design of 
vehicles and introduction of stealth characteristics and crosslinking, are key to achieving these 
goals. Release of the payload in the desired area of the body is the other significant challenge, 
however developments in stimuli-responsiveness and active targeting are proving very successful 
in the realization of this objective. 
It has been shown that there are many features in the design of new multifunctional nanoparticle 
drug delivery systems that can be varied; different combinations of amino acid building blocks 
and non-peptidic architectures, choice of targeting ligands, stimuli-responsive moieties and 
methods of stability enhancement, resulting in the opportunity to create a diverse library of 
nanodevices for all therapeutic eventualities. 
Ultimately, superior drug delivery systems will be created which will be smart, 
superfunctionalized nanodevices incorporating stealth properties, optimized biostability, stimuli-
sensitivity, active targeting and imagibility, as well as the function of the therapeutic payload. 
The potential impact of these superfunctionalized systems on the area of drug delivery is 
profound. 
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